Literature DB >> 14557859

Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype.

Sven G Gehrke1, Wolfgang Stremmel, Inge Mathes, Hans-Dieter Riedel, Karin Bents, Birgit Kallinowski.   

Abstract

Mild iron overload in chronic hepatitis C is associated with liver fibrosis, hepatitis C virus (HCV) genotype 1b infection, and an impaired response to interferon therapy. In this study we evaluated whether polymorphisms in the hemochromatosis gene HFE and the transferrin receptor gene TFR1 are associated with these typical findings. The study considered 246 HCV-infected patients and 200 blood donors as controls, in which C282Y, H63D, and S65C mutations ( HFE) and the S142G polymorphism ( TFR1) were detected. HCV genotype, serum ferritin levels, stainable intrahepatic iron, and grade of fibrosis according to the METAVIR score (F0-F4) were determined. In HCV-infected patients, heterozygosity for the C282Y mutation in HFE was significantly associated with elevated serum ferritin levels, stainable liver iron, and advanced fibrosis or cirrhosis (F2-F4). By multivariate logistic regression analysis the odds ratio for the development of advanced fibrosis or cirrhosis (F2-F4) was 2.5 for HCV-infected patients carrying a heterozygous C282Y mutation and 4.8 for HCV-infected patients with C282Y/H63D and C282Y/S65C compound heterozygosity. Heterozygosity for the C282Y mutation in HFE contributes to iron accumulation and fibrosis progression in chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557859     DOI: 10.1007/s00109-003-0493-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  33 in total

1.  A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.

Authors:  J N Feder; A Gnirke; W Thomas; Z Tsuchihashi; D A Ruddy; A Basava; F Dormishian; R Domingo; M C Ellis; A Fullan; L M Hinton; N L Jones; B E Kimmel; G S Kronmal; P Lauer; V K Lee; D B Loeb; F A Mapa; E McClelland; N C Meyer; G A Mintier; N Moeller; T Moore; E Morikang; C E Prass; L Quintana; S M Starnes; R C Schatzman; K J Brunke; D T Drayna; N J Risch; B R Bacon; R K Wolff
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

2.  Interaction between haemochromatosis and transferrin receptor genes in multiple myeloma.

Authors:  G F Van Landeghem; L E Beckman; A Wahlin; B Markevärn; L Beckman
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

3.  The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding.

Authors:  J N Feder; D M Penny; A Irrinki; V K Lee; J A Lebrón; N Watson; Z Tsuchihashi; E Sigal; P J Bjorkman; R C Schatzman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

4.  Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.

Authors:  Z J Bulaj; J D Phillips; R S Ajioka; M R Franklin; L M Griffen; D J Guinee; C Q Edwards; J P Kushner
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

5.  Measurements of iron status in patients with chronic hepatitis.

Authors:  A M Di Bisceglie; C A Axiotis; J H Hoofnagle; B R Bacon
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

6.  The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C.

Authors:  D Thorburn; G Curry; R Spooner; E Spence; K Oien; D Halls; R Fox; E A B McCruden; R N M MacSween; P R Mills
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

7.  HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis.

Authors:  Andreas Erhardt; Andrea Maschner-Olberg; Claudia Mellenthin; Günther Kappert; Ortwin Adams; Andreas Donner; Reinhard Willers; Claus Niederau; Dieter Häussinger
Journal:  J Hepatol       Date:  2003-03       Impact factor: 25.083

8.  Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.

Authors:  B C Smith; J Gorve; M A Guzail; C P Day; A K Daly; A D Burt; M F Bassendine
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

9.  Hepatitis C, iron status, and disease severity: relationship with HFE mutations.

Authors:  Bruce Y Tung; Mary J Emond; Mary P Bronner; Stuart D Raaka; Scott J Cotler; Kris V Kowdley
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

10.  Response to interferon alpha therapy is influenced by the iron content of the liver.

Authors:  D H Van Thiel; L Friedlander; S Fagiuoli; H I Wright; W Irish; J S Gavaler
Journal:  J Hepatol       Date:  1994-03       Impact factor: 25.083

View more
  7 in total

1.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 2.  The role of iron in the pathophysiology and treatment of chronic hepatitis C.

Authors:  Leslie Price; Kris V Kowdley
Journal:  Can J Gastroenterol       Date:  2009-12       Impact factor: 3.522

3.  The effect of iron depletion on chronic hepatitis C virus infection.

Authors:  Massimo Franchini; Giovanni Targher; Franco Capra; Martina Montagnana; Giuseppe Lippi
Journal:  Hepatol Int       Date:  2008-05-08       Impact factor: 6.047

Review 4.  Where are all the iron men and women?

Authors:  Freiderich C Luft
Journal:  J Mol Med (Berl)       Date:  2003-12       Impact factor: 4.599

5.  Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS study initial screening.

Authors:  James C Barton; Ronald T Acton; Catherine Leiendecker-Foster; Laura Lovato; Paul C Adams; John H Eckfeldt; Christine E McLaren; Jacob A Reiss; Gordon D McLaren; David M Reboussin; Victor R Gordeuk; Mark R Speechley; Richard D Press; Fitzroy W Dawkins
Journal:  Am J Hematol       Date:  2008-02       Impact factor: 10.047

Review 6.  Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy.

Authors:  Julie R Jonsson; David M Purdie; Andrew D Clouston; Elizabeth E Powell
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 7.  Genetic mechanisms and modifying factors in hereditary hemochromatosis.

Authors:  Günter Weiss
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11-17       Impact factor: 46.802

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.